Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

249P - A Retrospective Study on the Treatment Response of Locally Advanced Cervical Cancer Patients to Combination Chemoradiotherapy

Date

22 Nov 2020

Session

e-Poster Display Session

Topics

Cytotoxic Therapy;  Radiation Oncology

Tumour Site

Presenters

Siti Nabihah Sahralidin

Authors

S.N. Sahralidin1, R.M.J. Raden Mas Ismail2, J. Dato Khalid2, L. Chen1, S. Damit2, N. Saban2, K. Abdul Rahman2

Author affiliations

  • 1 Paprsb Institute Of Health Sciences, University Brunei Darussalam, BE1410 - Bandar Seri Begawan/BN
  • 2 The Brunei Cancer Centre, Pantai Jerudong Specialist Centre, BG3122 - Brunei Darussalam/BN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 249P

Background

Chemoradiotherapy (CCRT) is the primary treatment strategy for locally advanced cervical cancer (LACC) patients. Since June 2016, Brunei patients with LACC have been treated locally. However, no treatment response has been evaluated. As the first attempt in Brunei, this study aims to assess the treatment response of patients with LACC to the completing CCRT performed locally.

Methods

A retrospective cohort study on LACC patients referred to The Brunei Cancer Centre (TBCC) who met the inclusion criteria and had CCRT within the period between June 2016 and December 2019. Data was collected from TBCC patient database. All statistical analyses were carried out using R Studio Version 1.1.463 on Windows 10 where Shapiro-Wilk, Fisher’s exact and Mann-Whitney test was used. Inclusion criteria was confirmed histological diagnosis of squamous or adenocarcinoma or mixed LACC from stages IB to IIIB whom had started or completed CCRT within the period between June 2016 and December 2019. DFS is calculated in months starting from the completion of brachytherapy until the end of the study. OS is calculated in months starting from the time of diagnosis until the end of the study. Research proposal was granted ethics approval by the joint PAPRSB IHS Research and Ethics Committee and Medical and Health Research and Ethics Committee, Ministry of Health of Brunei Darussalam.

Results

40 patients were evaluated for analysis with mean age of 46.80 ± 12.23 years. Majority of the patients had a tumor diameter of ≥5cm (52.5%) and initial stage of 2B (55%). 90% of patients were compliant to chemotherapy. After completion of CCRT, 85% of patients had tumor regression. Upon follow-up, 10 patients had relapse with majority having initial stage of 2B (60%), tumor diameter of ≥5cm (90%) and tumor grade of G3 (70%). A significant difference was observed between the living status of patients, tumor response and tumor diameter in relapse and non-relapse patients with P values of <0.001, 0.002 and 0.009, respectively. 6 patients passed away due to cancer mortality.

Conclusions

There was an overall satisfactory outcome, tolerance and compliance to CCRT. Patients in high-risk group had higher incidence of relapse and had poor prognosis.

Clinical trial identification

Editorial acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.